极后区综合征:AQP4-IgG阳性NMOSD中的频率、诊断标准与严重程度
研究基于国际NMOSD数据库(n=430)分析AQP4-IgG阳性患者极后区综合征(APS)的频率,并对100例157次APS发作进行症状问卷评估。结果发现孤立性APS发作在起病时和病程中均常见,症状在免疫治疗后完全缓解。研究据此提出APS诊断标准并改造PUQE评分用于严重度分级,并在多中心前瞻性验证队列中展示其临床效用。
要点
- AQP4-IgG阳性NMOSD患者中孤立性APS发作常见,起病时占7.1%-10.3%,后续为9.4%-14.5%。
- 恶心中位持续14天,呕吐中位5次/天,呃逆中位持续14天,免疫治疗后症状完全缓解。
- 研究提出APS诊断标准并改造PUQE评分用于严重度分级,若发现背侧延髓病灶可在48小时内诊断APS发作。
核心结论
- 孤立性APS发作在AQP4-IgG阳性NMOSD起病时和病程中均常见。
- 本文提出的诊断标准有助于临床医生识别APS。
- 若检测到背侧延髓病灶,可在48小时内诊断APS发作。
- 准确诊断和评估APS发作严重程度有助于NMOSD临床试验的结局测量。
研究设计与样本
- 研究查询国际NMOSD数据库以确定APS频率,并对AQP4-IgG阳性NMOSD患者完成APS症状问卷。
- 恶心和呕吐严重程度来自妊娠独特呕吐量化(PUQE)评分。
- 诊断标准、严重度量表和免疫治疗反应应用于来自多个中心的前瞻性验证队列。
主要发现
- 国际数据库分析纳入430例AQP4-IgG血清阳性NMOSD患者,孤立性APS发作起病时占7.1%-10.3%,后续为9.4%-14.5%。
- 100例患者共157次APS发作中,恶心127次(81%)中位持续14天(范围2-365),呕吐113次(72%)中位5次/天(2-40)持续1-20分钟,呃逆102次(65%)中位持续14天(范围2-365)。
- 症状在免疫治疗后持续且完全缓解。
- 数据用于提出APS诊断标准并改造PUQE评分(呃逆严重度分级基于症状持续时间)。
- 临床效用在前瞻性验证队列中得到证明。
关键数值与推荐
- 孤立性APS发作起病时频率为7.1%-10.3%,后续频率为9.4%-14.5%(AQP4-IgG血清阳性NMOSD,n=430)。
- 恶心(n=127,81%)中位持续14天(范围2-365),呕吐(n=113,72%)中位5次/天(范围2-40)持续1-20分钟,呃逆(n=102,65%)中位持续14天(范围2-365)。
- 提出APS诊断标准和基于症状持续时间的呃逆严重度分级(改造PUQE评分)。
- 若检测到背侧延髓病灶,可在48小时内诊断APS发作。
临床怎么用
- 本文提出的诊断标准有助于临床医生识别APS。
- 若检测到背侧延髓病灶,可在48小时内诊断APS发作。
- 准确诊断和评估APS发作严重程度有助于NMOSD临床试验的结局测量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define the frequency, duration, and severity of intractable nausea, vomiting, or hiccups in aquaporin-4-immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) and propose diagnostic criteria and a severity scale for area postrema syndrome (APS). METHODS: An International NMOSD database was interrogated for frequency of APS. Patients with AQP4-IgG-positive NMOSD completed an APS symptom questionnaire. Nausea and vomiting severity was derived from the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score. The diagnostic criteria, severity scale, and immunotherapy response was applied to a prospective validation cohort of patients from multiple centers. RESULTS: Analysis of an international database for AQP4-IgG-seropositive NMOSD (n = 430) revealed a high prevalence of isolated APS attacks (onset 7.1%-10.3%; subsequent 9.4%-14.5%) across continents. For 100 patients with 157 episodes of APS, nausea (n = 127, 81%) lasted for a median of 14 days (range 2-365), vomiting (113, 72%) with a median of 5 episodes/d (2-40) lasted 1-20 minutes, and hiccups (102, 65%) lasted a median of 14 days (2-365). Symptoms consistently and completely resolved following immunotherapy. Data were used to propose APS diagnostic criteria and repurpose PUQE score (hiccups severity grade based on symptom duration). The clinical utility was demonstrated in a prospective validation cohort. CONCLUSION: Isolated APS attacks are frequently encountered both at onset and during the NMOSD course. The diagnostic criteria proposed here will assist clinicians in recognizing APS. Diagnosis of an APS attack earlier than 48 hours is possible if a dorsal medulla lesion is detected. Accurate diagnosis and evaluation of APS attack severity will assist in outcome measurement in NMOSD clinical trials.
引用
- Shosha E, Dubey D, Palace J, et al. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology. 2018. PMID: 30258024. doi:10.1212/WNL.0000000000006392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。